Traws Pharma, Inc. (NASDAQ: TRAW) has released its financial results for the year ending December 31, 2024, alongside ...

Tivoxavir marboxil’s potential as a single dose therapeutic agent for bird flu supported by significant antiviral activity in ...

Werner Cautreels, PhD, to retire as CEO, while continuing as a Board MemberIain D. Dukes, D Phil, Executive Board Chairman, ...

Traws Pharma, Inc. ( NASDAQ: TRAW) Virtual Investor Event March 31, 2025 10:00 AM ET Werner Cautreels – Chief Executive Officer Robert Redfield – Chief Medical Officer David Pauza – Chief Science ...

Reports FY24 revenue $226,000 vs $226,000 last year. “I believe Traws made outstanding progress over the last year. We re-defined our focus – ...

TRAWS PHARMA ($TRAW) posted quarterly earnings results on Monday, March 31st. The company reported earnings of $95.66 per share, beating estimates of -$9.74 by $105. ...

Spectrum Science, a 2024 MM+M Agency 100 honoree, hired Jill Beene as president of advertising and consulting, Lauren Ankeles as EVP of operations and transformation, as well as Natalie Newman as ...

NEWTOWN, Pa., March 24, 2025 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (NASDAQ: TRAW) (“Traws Pharma”, “Traws” or “the Company”), a clinical-stage biopharmaceutical company developing novel therapies to ...

NEWTOWN, Pa., March 31, 2025 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (NASDAQ: TRAW) (“Traws Pharma”, “Traws” or “the Company”), a clinical-stage ...

Werner Cautreels, PhD, to retire as CEO, while continuing as a Board Member Iain D. Dukes, D Phil, Executive Board Chairman, to become Interim CEO NEWTOWN, Pa., March 28, 2025 (GLOBE NEWSWIRE ...

Tivoxavir marboxil’s potential as a single dose therapeutic agent for bird flu supported by significant antiviral activity in three well accepted animal models and positive Phase 1 data Ongoing ...